Roadmap for developing and validating therapeutically
Qualitative and quantitative changes in the process of protein synthesis is a common response of cells to stress, and melanoma cells use this strategy to survive drug treatment and colonize new organs.
Blocking this adaptive response therefore presents a promising therapeutic strategy, however drugs that specifically target protein synthesis adaptation in cancer cells, without affecting normal cells, have yet to be developed.
Majority of patients present at advanced stage, owing to occult anatomic location, non-specific symptoms and hence, delayed diagnosis.
Although currently evaluated and staged according to the criteria derived for skin melanomas (SM), evidence to support this practice in AM is lacking.
Young Investigators are scientists within four years of their first academic faculty appointment.
A mentorship commitment from a senior investigator is required.
The targeting of melanoma-specific protein synthesis would leave normal cells unharmed thereby reducing toxicity for patients.
In summary, we propose to greatly expand the diversity of treatment options available to melanoma patients by using small molecules to access the rich and largely untapped inventory of intracellular metabolic enzyme targets for cancer immunotherapy.
To investigate this question, we will build animal models that allow researchers for the first time to compare immune responses between tumors, and to understand why melanomas are different, and what keeps immune cells from attacking melanomas (and other cancers) before treatment.
The answers to these questions are crucial, as even the best immunotherapy combinations protect less than half of the patients with melanomas.
Recent conceptual and technological advances promote our understanding of the origins and nature of cancer metastasis.
This program aims to attract early career scientists with novel ideas into melanoma research, thereby recruiting and supporting the next generation of melanoma researchers.